Palbociclib is a medication used to treat estrogen receptor-positive breast cancer as well as advanced HER2-negative breast cancer. It is typically prescribed in combination with letrozole and fulvestrant. Clinical studies show that this medicine and letrozole delay disease progression in patients for a time nearly twice as long as in the case where only letrozole is taken. Palbociclib suppliers and distributors market the drug as 75mg, 100mg, and 125mg oral capsules. The developer and the sole manufacturer is Pfizer, who acquired approval to market the drug in 2015 and distributes it under the trade name Ibrance. Ibrance is currently available in over 90 countries globally, and, due to patent protection, other pharmaceutical substance manufacturers have yet to join the market with their formulations. Alternatives to palbociclib that are also indicated as treatments for HER2-negative breast cancer include abemaciclib by manufacturer and supplier Eli Lilly and ribociclib by Novartis. It is available as a capsule to be swallowed. It's typically taken once a day for the first 21 days of a daily cycle. The number of times you should complete this cycle will be determined by your doctor. This pharmaceutical substance should be taken at the exact time each day. Need not break, crush, or smash the capsules; they must be swallowed whole. Broken or cracked capsules should not be consumed. Do not take another dosage if you puke after taking this medicine. Maintain your normal dosage schedule.

Palbociclib is a cell cycle kinase 4/6 (CDK4/6) inhibitor1 with such an IC50 of 9-15 nmol/L that works by attaching to the ATP gap. It's vital to keep in mind that it has little to no activity against the other kinases. The CDK4/6 kinase is implicated in the G1-S phase, together with its coregulatory companion cyclin D. As a result, inhibiting this step hinders cellular proliferation in cells that use this route. The mechanisms of phosphorylation of mitogen-activated protein kinase and the E2F group of transcriptional regulators are included in this phase. Palbociclib reduces cell proliferation and decreases the Replication of DNA in tumor suppressor gene (RB) proficient cancer cells due to its method of action. As anticipated, the fraction of cells in the G1 state increases significantly in these RB cells, and the addition of this substance causes efficient depolymerization of RB, reduced proliferation, and induced senescence, resulting in cell-cycle stop. Palbociclib can suppress cellular proliferation of estrogen receptor-positive human breast cancer cells by inhibiting cell-cycle progression from G1 to S phase, according to in vitro research. The responsiveness of the cells was shown to rise greatly with the development of RB1 and CCND1 and the low expression of CDKN2A in this study. This pharmaceutical substance increased in vivo anticancer activity in estrogen receptor-positive breast cancer model organisms when coupled with antiestrogens. Palbociclib is mostly metabolized in the liver, with the cytochrome P450 immunoreactive 3A and sulfotransferase 2A1 performing the majority of the work. This pharmaceutical substance’s metabolism is dominated by oxidative and sulfonation processes, with acylation and gluconeogenesis as minor events. It generates mostly inert glucuronide and findings are as follows: acid conjugates during metabolism. The glucuronide compound is the most common circulating metabolite, providing for 1.5 percent of the dosage in excreta.

The for a month’s supply of palbociclib is considerably high. Retail prices per 21 capsules of the drug fall into an approximate range of 3,500 EUR to 4,000 EUR. Pharmaceutical specialists are welcome to browse through offers of these pharmaceutical substance capsules for sale from it’s suppliers and distributors on our pharmaceutical marketplace, or else seek out further useful medical information about this substance online at the official Ibrance website.

Being a global B2B pharmaceutical online marketplace, Pipelinepharma is structured to simplify pharmaceutical deals by providing you with an intuitive interface that is easy to engage with. The selection of Palbociclib offerings can be narrowed down with the use of filters and easily weighed against one another according to medication prices and commercial terms. The advanced filters help you filter out the countries for these pharmaceutical substance’s manufacturers and suppliers that you are looking for. These also enable you to check the dossier status of this medicine, and the GMP approvals of the different variants of this medicine. Also, each manufacturer or supplier product description contains essential information about this medicine including clinical data, stability zones, countries where it is already registered in. Manufacturers also have special, and delivery terms.

If you are a pharmaceutical licensing company or a distributor you can enter into deals or negotiations over Palbociclib offers with manufacturing companies after completing the free registration process and joining our online marketplace. This helps to ensure that you conclude the pharmaceutical deal at a reasonable cost and achieve the best cost/benefit ratio for your company while bypassing lengthy sourcing, negotiation, and ordering process. Once you have finalized a deal, you can look forward to a long-lasting business relationship with the manufacturers or suppliers. This way, the marketplace allows you as a distributor to skip the process of shortlisting product manufacturers every time you are looking for in-licensing or distribution deals.

To keep up to the quality standards other than Good Manufacturing Practice approvals that Palbociclib manufacturers list has, we qualify their companies before they are boarded on the platform. This allows us to screen these manufacturers for the quality of the pharmaceutical products’ dossiers and protect against the risk of possible malpractices.